Belite Bio, Inc
BLTE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $10,307 | $11,049 | $9,396 | $7,254 |
| G&A Expenses | $12,711 | $6,547 | $6,121 | $4,203 |
| SG&A Expenses | $12,711 | $6,547 | $6,121 | $4,203 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $23,018 | $17,596 | $15,517 | $11,457 |
| Operating Income | -$23,018 | -$17,596 | -$15,517 | -$11,457 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,328 | $1,276 | $1,240 | $1,357 |
| Pre-Tax Income | -$21,690 | -$16,320 | -$14,277 | -$10,100 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$21,690 | -$16,320 | -$14,277 | -$10,100 |
| % Margin | – | – | – | – |
| EPS | -0.65 | -0.5 | -0.44 | -0.32 |
| % Growth | -30% | -13.6% | -37.5% | – |
| EPS Diluted | -0.65 | -0.5 | -0.44 | -0.32 |
| Weighted Avg Shares Out | 33,223 | 32,585 | 32,084 | 31,453 |
| Weighted Avg Shares Out Dil | 33,223 | 32,585 | 32,084 | 31,453 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $42 | $42 | $0 |
| EBITDA | -$21,690 | -$16,278 | -$15,475 | -$7,579 |
| % Margin | – | – | – | – |